Cargando…
Study protocol: high-dose mizoribine with prednisolone therapy in short-term relapsing steroid-sensitive nephrotic syndrome to prevent frequent relapse (JSKDC05 trial)
BACKGROUND: Eighty percent of children with steroid-sensitive nephrotic syndrome (SSNS) relapse within 2 years and 40–50% patients show frequently-relapsing nephrotic syndrome (FRNS). Patients showing a relapse within 6 months after initial remission are at high risk of FRNS. Since frequent predniso...
Autores principales: | Hama, Taketsugu, Nakanishi, Koichi, Ishikura, Kenji, Ito, Shuichi, Nakamura, Hidefumi, Sako, Mayumi, Saito-Oba, Mari, Nozu, Kandai, Shima, Yuko, Iijima, Kazumoto, Yoshikawa, Norishige |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131840/ https://www.ncbi.nlm.nih.gov/pubmed/30200895 http://dx.doi.org/10.1186/s12882-018-1033-z |
Ejemplares similares
-
Study protocol: mycophenolate mofetil as maintenance therapy after rituximab treatment for childhood-onset, complicated, frequently-relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicenter double-blind, randomized, placebo-controlled trial (JSKDC07)
por: Horinouchi, Tomoko, et al.
Publicado: (2018) -
Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial)
por: Nagano, China, et al.
Publicado: (2019) -
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment
por: Yoshikawa, Norishige, et al.
Publicado: (2015) -
Rituximab for nephrotic syndrome in children
por: Iijima, Kazumoto, et al.
Publicado: (2016) -
Rituximab Treatment for Nephrotic Syndrome in Children
por: Iijima, Kazumoto, et al.
Publicado: (2014)